RxDoctor Payments Data

William Tamborlane

Pediatric Endocrinology · New Haven, CTNPI 1124001342

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $146,105 of the $181,841 with a category attached, or 80.3%. 12 manufacturers reported payments, led by Boehringer Ingelheim at 56.8% of the total. Reporting peaked in 2019 at $69,044 and has fallen 98.8% since, to $857 in 2024. Among pediatric endocrinology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$181,841in general payments, 2019–2025

Across 91 payments — averaging $1998.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$103K
  • Medtronic$32K
  • Novo Nordisk$14K
  • Novo Nordisk AS$11K
  • Ipsen Bioscience Inc.$9K
  • Boehringer Ingelheim International GmbH$6K
  • plus $7K from 6 others
$936,816in research payments, 2019–2025

Across 293 payments — averaging $3197.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$239K
  • Takeda Pharmaceuticals U.S.A., Inc.$200K
  • Novo Nordisk$189K
  • Astrazeneca UK Limited$137K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$63K
  • Sanofi US Services Inc.$59K
  • plus $51K from 3 others

What the payments were for

  • Consulting fees$146,10580%
  • Speaking & faculty fees$29,09316%
  • Travel & lodging$5,0293%
  • Food & beverage$1,6141%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim26$103,276
Medtronic(2 entities)27$31,924
Novo Nordisk15$14,383
Novo Nordisk AS3$10,813
Ipsen Bioscience Inc.1$9,000
Boehringer Ingelheim International GmbH10$5,943
Eisai Inc.3$3,850
Sanofi-aventis U.S. LLC1$2,340
Companion Medical, Inc.2$140
AstraZeneca1$132
Lilly USA, LLC1$24
Tandem Diabetes Care, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$181,841 in reported general payments places this provider in the 90th percentile of 31 pediatric endocrinology providers in Connecticut.

See all pediatric endocrinology providers in Connecticut

Other pediatric endocrinology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →